Cure8 trial brief
Changes in gut permeability are thought to relate to intestinal barrier function and symptoms in UC and IBS-D. If Aquamin alters permeability, it could suggest a mechanism for symptom or disease-modifying effects and justify larger trials.
Adults with ulcerative colitis (remission or mild), people with IBS-D, clinicians interested in dietary supplements and barrier function, and researchers studying mineral supplements or gut permeability biomarkers.
This is a Phase 2 interventional trial (NCT04855799) testing Aquamin®, a multi-mineral extract from red marine algae, for effects on gastrointestinal permeability in people with ulcerative colitis (in remission or mild), IBS-D, and healthy volunteers.
The primary outcome was change in the urine lactulose:mannitol ratio over 90 days; lactulose measurements were not available but mannitol levels were measured. Participants took Aquamin (4 capsules/day, ~800 mg calcium/day) for 90 days. The record is a sub-study of a larger Aquamin trial (NCT03869905).
This entry is a clinicaltrials.gov registry record for a completed Phase 2 study. The registry notes lactulose could not be measured and reports mannitol levels instead. Results summary or peer-reviewed publication are not provided in this record; interpret any efficacy implications cautiously and look for full results or publications.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
